Security key
15673T100
Century Therapeutics, Inc. - Common Stock, par value $0.0001 per share (IPSC)
CUSIP: 15673T100
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 22,628,192
- Total 13F value
- $12,642,486
- Share change
- -6,936,251
- SEC-reported price per share
- $0.56
- Number of holders
- 64
- Value change
- -$3,582,180
- Number of buys
- 36
- Number of sells
- 45
- Shares outstanding
- 180,747,818
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
64
Top holders
10
IPSC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Century Therapeutics, Inc. SEC filings
Century Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 15673T100
Recent filing periods:
Ownership snapshot
Top reported holders of IPSC - Century Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Casdin Capital, LLC
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
Lead comparable stake: 3.7%
13D/G row: Casdin Capital, LLC
Showing 1-6 of 15 holder rows.
Quick read
Casdin Capital, LLC leads the comparable SEC ownership view at 3.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Casdin Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Casdin Capital, LLC
3.7%
Bain Capital Life Sciences Invest...
3%
BlackRock, Inc.
1.7%
FMR LLC
1.4%
Venrock Adviser, LLC
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Casdin Capital, LLC |
13D/G
13F
Company
|
3.7%
|
$1,702,527
3,212,316 shares
|
$0 | 31 Mar 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
3%
|
$2,575,332
5,410,361 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
1.7%
|
$1,436,813
3,018,515 shares
|
— | 31 Mar 2025 |
| FMR LLC |
13F
Company
|
1.4%
|
$1,235,099
2,594,745 shares
|
— | 31 Mar 2025 |
| Venrock Adviser, LLC |
13F
Company
|
1.4%
|
$1,189,081
2,498,069 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.3%
|
$1,131,688
2,377,494 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
64
Shares
22,628,192
Rows available
64
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
69
Q2 2025 holders
64
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend